Compare BV & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BV | FTRE |
|---|---|---|
| Founded | 1939 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2018 | 2023 |
| Metric | BV | FTRE |
|---|---|---|
| Price | $12.75 | $15.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $14.50 | $14.06 |
| AVG Volume (30 Days) | 631.6K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $4.61 | N/A |
| Revenue Next Year | $1.90 | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $11.06 | $3.97 |
| 52 Week High | $17.11 | $18.67 |
| Indicator | BV | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 68.84 |
| Support Level | $12.56 | $9.01 |
| Resistance Level | $12.93 | $18.26 |
| Average True Range (ATR) | 0.36 | 0.69 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 78.77 | 87.80 |
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.